FDA Approves ASMANEX (R) TWISTHALER(R) (Mometasone Furoate Inhalation Powder) for the Once Daily Maintenance Treatment of Asthma in Children...(ASMANEX may increasethe risk of some eye...),Health

Use ASMANEX as directed by your health care provider, since its ability to work in your lungs depends on regular use. If a patient's asthma symptoms do not improve, or get worse, they should contact their health care provider.

The most common side effects with ASMANEX TWISTHALER include headache, nasal allergy symptoms, sore throat, upper respiratory infection, sinus infection, fungal infections of the mouth, painful menstrual periods, muscle and bone pain, back pain, and upset stomach.

Full prescribing information is available at: http://www.spfiles.com/piasmanex.pdf.

About Schering-Plough Corporation

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. In November 2007, Schering-Plough acquired Organon BioSciences, with its Organon human health and Intervet animal health businesses, marking a pivotal step in the company's ongoing transformation. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its approximately 50,000 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the potential market for ASMANEX. Forward-looking
'/>"/>